Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Samyang Holdings
Seoul, South Koreasamyang.com ↗
- Ownership
- Private
- Employees
- ~380
- Development stage
- Commercial
01
Overview
Samyang Holdings’ biopharmaceutical division has commercialized polymer-based biodegradable sutures globally and developed cytotoxic anticancer drugs for solid and blood cancers. The company continues to invest in R&D for innovative drug delivery technologies and genetic therapies. It operates manufacturing plants in Korea and Hungary with a US subsidiary focused on open innovation. Clinical results are not detailed publicly but products are available commercially.
- Therapeutic areas
- OncologyOther
- Modalities
- Small molecules (anticancer drugs)Gene therapeuticsMedical devices (biodegradable polymers/sutures)Proprietary drug delivery systems
- Industry
- Biotech
Beyond the preview
Go deeper on Samyang Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Samyang Holdings.